Asian J Psychiatr. 2024 Dec 11;103:104317. doi: 10.1016/j.ajp.2024.104317. Online ahead of print.
ABSTRACT
Neuroscience-based Nomenclature (NbN) is a pharmacologically-driven classification of psychotropics, aiming to revise the current indication-based classification (antipsychotics, antidepressants, anxiolytics etc.). Whereas the number of psychotropics has risen dramatically over the years, the current nomenclature preserves a rather narrow categorization that overlooks the rich neurobiological knowledge accumulated to date. The current classification is confusing for the patients (“Why am I getting an ‘antipsychotic’ for my depression, Doctor? am I psychotic?”), and consequently interfering with optimal care. To address this issue, leading organizations in psychopharmacology have collaborated to introduce a classification which is based on pharmacological domains (neurotransmitters) and mode of action. This approach may relieve patients from confusing labels and help clinicians plan the next pharmacological step from a neuroscientific prism. NbN has earned endorsements from significant psychiatric bodies (including the American Psychiatric Association and the European Psychiatric Association) and has been incorporated into highly ranked peer-reviewed journals, textbooks, and educational programs. It is accessible through a free app, offering an easy-to-navigate database for professionals, as well as specialized versions for child and adolescent psychiatry and for patient and family education. By bridging the gap between complex neurobiological research and clinical practice, NbN may enhance evidence-based prescription practice and serve as an educational resource. Despite its inherent challenges, this initiative may represent a step towards integrating neuroscience into everyday psychiatric care, making it more understandable and relevant for all involved.
PMID:39740260 | DOI:10.1016/j.ajp.2024.104317
